DPDoctor's PassportEducation
Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.
RapidMLAMSRAFoundation

Penicillin allergy assessment

Essential points for quick revision.

!
Escalate

Current wheeze, hypotension, airway swelling, widespread urticaria or rapidly progressive mucocutaneous blistering after a medicine is an emergency. Stop the suspected drug, treat anaphylaxis through Resuscitation Council UK guidance and obtain urgent specialist help for severe cutaneous reactions.

Synopsis

Replace an imprecise penicillin-allergy label with a structured phenotype, distinguish intolerance from immediate or severe delayed hypersensitivity, and select safe testing or antibiotic alternatives.

  • Ask which drug was taken, why, route, timing after the dose, symptoms, treatment, hospitalisation, time since reaction and subsequent beta-lactam tolerance.
  • Nausea, diarrhoea, headache, family history or an unknown childhood label is not equivalent to IgE-mediated allergy, although uncertainty still needs safe documentation.
  • Immediate urticaria, angio-oedema, bronchospasm or hypotension suggests an immediate hypersensitivity phenotype; severe blistering, mucosal or organ injury indicates a high-risk delayed reaction.

Key red flags

Immediate hypersensitivity phenotype

Rapid urticaria, angio-oedema, wheeze, throat symptoms, hypotension or collapse after a beta-lactam suggests IgE-mediated or other immediate allergy.

Investigation priorities

01
Structured allergy historyFirst step

Classify culprit, timing, symptoms, severity, treatment and subsequent tolerance before choosing any test.

Management branches

History at prescribingCreate a usable phenotype

A patient reports penicillin allergy when antibacterial treatment is being considered.

  1. Ask exact drug, indication, dose-to-symptom timing, manifestations, treatment, admission and later tolerated beta-lactams; examine current reaction if present.
  2. Classify as likely intolerance, low-risk uncertain, immediate hypersensitivity or severe delayed reaction and record uncertainty explicitly.
Open full textbook Answer 2 questions
Sources and review status4 sources · checked 27 Aug 2026 · clinical review pending
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom